Abstract

The advent of chimeric antigen receptor (CAR) technology has catalyzed a paradigm shift in cancer treatment. While CAR-T therapies have shown remarkable success in hematological malignancies, their limitations— especially in treating solid tumors—necessitate alternative strategies. CAR- NK cell therapy emerges as a promising immunotherapeutic platform that combines the innate cytotoxicity of NK cells with the precision of CAR targeting. This review provides an updated perspective on the development, advantages, and current challenges of CAR-NK cells, underscoring their lower toxicity, “off-the-shelf” potential, and applicability in both blood cancers and solid tumors. Technological innovations, clinical trials, and synthetic biology strategies are also explored, highlighting the future trajectory of CAR-NK therapies.

Keywords

emerging cancer,combines the power, immune system,genetically modified, peripheral blood, umbilical cord blood